… Ulcerative colitis (UC) and Crohn's disease (CD) are chronic idiopathic inflammatory
bowel diseases (IBDs) for which no medical cure presently exists. Patients with moderate-to-severe …

… However, in GEMINI LTS, vedolizumab was associated with lower rates of colon and rectal
… Although this analysis includes longer cumulative exposure to vedolizumab, the rate of …

… Vedolizumab is a novel monoclonal antibody used in patients with inflammatory bowel
disease, … inflammatory bowel disease exposed to vedolizumab versus those on other treatment. …

… do not respond to vedolizumab treatment despite sufficient drug exposure in the blood … ,
we investigated vedolizumab tissue exposure and explored whether insufficient tissue exposure …

… to characterise the relationship between vedolizumab exposure and response using patient-…
affecting vedolizumab drug clearance and serum levels [10]. Potential target vedolizumab …

… of vedolizumab exposure, 32 752 patients reported 80 218 events. In patients with Crohn’s
disease or ulcerative colitis, … in patients with Crohn's disease or ulcerative colitis in the post-…

… in both ulcerative colitis (UC) and Crohn’s disease (CD). … in tumor necrosis factor-alpha-exposed
CD patients. To date, … apparent exposure-response relationship, vedolizumab has …

… Authors found no increased risk of any infection or serious infection with vedolizumab
exposure compared with placebo. Furthermore, infusion reactions were described in ≤5% of …

… Vedolizumab is effective for induction and maintenance of inflammatory bowel disease with
… 2830 UC and CD patients with 4811 patient-years of vedolizumab exposure [60]. Notably, …

… vs infliximab and vedolizumab vs subcutaneous TNF … Subgroup comparison in TNF-antagonist–naïve
and –exposed … with vedolizumab in TNF-antagonist–exposed individuals. …